These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 7696838

  • 1. Molecular dynamics conformations of deltorphin analogues advocate delta opioid binding site models.
    Bryant SD, Attila M, Salvadori S, Guerrini R, Lazarus LH.
    Pept Res; 1994; 7(4):175-84. PubMed ID: 7696838
    [Abstract] [Full Text] [Related]

  • 2. Helix-inducing alpha-aminoisobutyric acid in opioid mimetic deltorphin C analogues.
    Bryant SD, Guerrini R, Salvadori S, Bianchi C, Tomatis R, Attila M, Lazarus LH.
    J Med Chem; 1997 Aug 01; 40(16):2579-87. PubMed ID: 9258365
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of 1-aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique delta and mu opioid activity in modified peptides.
    Breveglieri A, Guerrini R, Salvadori S, Bianchi C, Bryant SD, Attila M, Lazarus LH.
    J Med Chem; 1996 Feb 02; 39(3):773-80. PubMed ID: 8576920
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative analysis of various proposed models of the receptor-bound conformation of H-Tyr-Tic-Phe-OH related delta-opioid antagonists.
    Wilkes BC, Schiller PW.
    Biopolymers; 1995 Feb 02; 37(6):391-400. PubMed ID: 8589244
    [Abstract] [Full Text] [Related]

  • 8. Topographical requirements for delta-selective opioid peptides.
    Nikiforovich GV, Hruby VJ, Prakash O, Gehrig CA.
    Biopolymers; 1991 Jul 02; 31(8):941-55. PubMed ID: 1782355
    [Abstract] [Full Text] [Related]

  • 9. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
    Schmidt R, Wilkes BC, Chung NN, Lemieux C, Schiller PW.
    Int J Pept Protein Res; 1996 Nov 02; 48(5):411-9. PubMed ID: 8956074
    [Abstract] [Full Text] [Related]

  • 10. Postnatal development of delta-opioid receptor subtypes in mice.
    Negri L, Severini C, Lattanzi R, Potenza RL, Melchiorri P.
    Br J Pharmacol; 1997 Mar 02; 120(6):989-94. PubMed ID: 9134207
    [Abstract] [Full Text] [Related]

  • 11. Comparative conformational analyses of mu-selective dermorphin and delta-selective deltorphin-II in aqueous solution by 1H-NMR spectroscopy.
    Segawa M, Ohno Y, Doi M, Inoue M, Ishida T, Iwashita T.
    Int J Pept Protein Res; 1994 Sep 02; 44(3):295-304. PubMed ID: 7822107
    [Abstract] [Full Text] [Related]

  • 12. Dermenkephalin and deltorphin I reveal similarities within ligand-binding domains of mu- and delta-opioid receptors and an additional address subsite on the delta-receptor.
    Charpentier S, Sagan S, Delfour A, Nicolas P.
    Biochem Biophys Res Commun; 1991 Sep 30; 179(3):1161-8. PubMed ID: 1656944
    [Abstract] [Full Text] [Related]

  • 13. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
    Shenderovich MD, Liao S, Qian X, Hruby VJ.
    Biopolymers; 2000 Jun 30; 53(7):565-80. PubMed ID: 10766952
    [Abstract] [Full Text] [Related]

  • 14. Conformationally restricted deltorphin analogues.
    Schiller PW, Weltrowska G, Nguyen TM, Wilkes BC, Chung NN, Lemieux C.
    J Med Chem; 1992 Oct 16; 35(21):3956-61. PubMed ID: 1331451
    [Abstract] [Full Text] [Related]

  • 15. Substitution of aromatic and nonaromatic amino acids for the Phe3 residue in the delta-selective opioid peptide deltorphin I: effects on binding affinity and selectivity.
    Heyl DL, Schmitter SJ, Bouzit H, Johnson TW, Hepp AM, Kurtz KR, Mousigian C.
    Int J Pept Protein Res; 1994 Nov 16; 44(5):420-6. PubMed ID: 7896499
    [Abstract] [Full Text] [Related]

  • 16. On the degradation of the deltorphin peptides by plasma and brain homogenate.
    Marastoni M, Tomatis R, Balboni G, Salvadori S, Lazarus LH.
    Farmaco; 1991 Nov 16; 46(11):1273-9. PubMed ID: 1667359
    [Abstract] [Full Text] [Related]

  • 17. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ.
    J Med Chem; 1996 Sep 27; 39(20):4120-4. PubMed ID: 8831778
    [Abstract] [Full Text] [Related]

  • 18. Impact of 1,5-disubstituted tetrazole ring on chelating ability of delta-selective opioid peptide.
    Łodyga-Chruścińska E, Ołdziej S, Micera G, Sanna D, Chruściński L, Olczak J, Zabrocki J.
    J Inorg Biochem; 2004 Mar 27; 98(3):447-58. PubMed ID: 14987845
    [Abstract] [Full Text] [Related]

  • 19. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E, Tourwé D, Kertész I, Tóth G, Borsodi A, Benyhe S.
    Brain Res Bull; 2007 Sep 14; 74(1-3):119-29. PubMed ID: 17683797
    [Abstract] [Full Text] [Related]

  • 20. [Aladan3]TIPP: a fluorescent delta-opioid antagonist with high delta-receptor binding affinity and delta selectivity.
    Chen H, Chung NN, Lemieux C, Zelent B, Vanderkooi JM, Gryczynski I, Wilkes BC, Schiller PW.
    Biopolymers; 2005 Sep 14; 80(2-3):325-31. PubMed ID: 15614807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.